Pacer Advisors’s Spero Therapeutics SPRO Stock Holding History

Pacer Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,608	Closed	-$24K	–	1543
2021 Q1	$24K	Buy	+1,608	New	+$28.3K	﹤0.01%	1498

Other funds holding SPRO

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Pacer Advisors's SPRO Position: Q2 2021 in Review

Pacer Advisors sold out of Spero Therapeutics (SPRO) in Q2 2021, closing a stake of 1,608 shares — an estimated $24K sold.

Pacer Advisors first reported a position in SPRO in Q1 2021 and held it in 1 quarter. The position peaked at $24K in Q1 2021. 88 funds tracked by Wall St. Rank hold SPRO as of Q2 2021.

Pacer Advisors reported no remaining Spero Therapeutics position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 1,608 Spero Therapeutics shares in Q2 2021, an estimated $24K.
Pacer Advisors first reported a position in Spero Therapeutics in Q1 2021 and held it in 1 quarter.
Pacer Advisors's Spero Therapeutics position peaked at $24K in Q1 2021.
88 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.